{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T18:09:42Z","timestamp":1711390182005},"reference-count":106,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1586\/ehm.11.19","type":"journal-article","created":{"date-parts":[[2011,6,14]],"date-time":"2011-06-14T20:42:02Z","timestamp":1308084122000},"page":"285-299","source":"Crossref","is-referenced-by-count":4,"title":["Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients"],"prefix":"10.1586","volume":"4","author":[{"given":"Devendra K","family":"Hiwase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah L","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"CIT0001","first-page":"1497","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"CIT0004","doi-asserted-by":"crossref","unstructured":"Deininger M, O\u2019Brien SG, Guilhot Fet al.International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Presented at:51st Annual Meeting of American Society of Hematology. New Orleans, LA, USA, 5\u20138 December 2009.","DOI":"10.1182\/blood.V114.22.1126.1126"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3800"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1451"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0025"},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"CIT0010","doi-asserted-by":"crossref","unstructured":"Hehlmann R, Jung-Munkwitz S, Lauseker Met al.Superior CMR-rates with tolerability-adapted imatinib 800 mg vs 400 mg vs 400 mg + IFN in CML: the randomized German CML-study IV. Presented at:52nd Annual Meeting of American Society of Hematology. Orlando, FL, USA, 4\u20137 December 2010.","DOI":"10.1182\/blood.V116.21.357.357"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2007-08-103499","volume":"113","author":"Castagnetti","year":"2009","journal-title":"Blood"},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"CIT0014","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"CIT0015","unstructured":"Palandri F, Castagnetti F, Iacobucci Iet al.The combination of interferon-\u03b1 with imatinib in early chronic phase chronic myeloid leukemia patients induces a significant improvement of the molecular responses in the first two years of treatment: results from three studies from the GIMEMA CML working party. Presented at:51st Annual meeting of American Society of Hematology. New Orleans, LA, USA, 5\u20138 December 2009."},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2009-02-200543","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"CIT0018","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"CIT0019","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"CIT0020","doi-asserted-by":"crossref","unstructured":"Rosti G, Castagnetti F, Gugliotta Get al.excellent outcomes at 3 years with nilotinib 800 mg daily in early chronic phase, Ph+chronic myeloid leukemia (CML): results of a Phase 2 GIMEMA CML WP clinical trial. Presented at:52nd Annual Meeting of American Society of Hematology. Orlando, FL, USA, 4\u20137 December 2010.","DOI":"10.1182\/blood.V116.21.359.359"},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"key":"CIT0022","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"CIT0023","unstructured":"Hughes T, Hochhaus A, Saglio Get al.ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Presented at:52nd Annual Meeting of American Society of Hematology. Orlando, FL, USA, 4\u20137 December 2010."},{"key":"CIT0024","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"CIT0025","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"CIT0026","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"Hasford","year":"1998","journal-title":"J. Natl Cancer Inst."},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1103"},{"key":"CIT0028","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1200\/JCO.2006.09.9499","volume":"25","author":"White","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"CIT0029","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4687"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093617"},{"key":"CIT0032","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","volume":"28","author":"White","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0694"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100268"},{"key":"CIT0035","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1200\/JCO.2008.19.4076","volume":"27","author":"Zhang","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"CIT0036","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"CIT0037","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","volume":"112","author":"Giannoudis","year":"2008","journal-title":"Blood"},{"key":"CIT0038","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","volume":"158","author":"Hegedus","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"CIT0039","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"CIT0040","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2404139","volume":"20","author":"Ross","year":"2006","journal-title":"Leukemia"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1134"},{"key":"CIT0042","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"CIT0043","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"CIT0044","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"CIT0045","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","volume":"115","author":"Alvarado","year":"2009","journal-title":"Cancer"},{"key":"CIT0046","doi-asserted-by":"crossref","unstructured":"Hughes TP, Hochhaus A, Branford Set al.Reduction of BCR\u2013ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: an analysis from the international randomized study of interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP). Presented at:50th Annual Meeting of American Society of Hematology. San Francisco, CA, USA, 6\u20139 December 2008.","DOI":"10.1182\/blood.V112.11.334.334"},{"key":"CIT0047","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"CIT0048","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"CIT0049","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"CIT0050","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"CIT0051","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"Marin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404318"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2896"},{"key":"CIT0054","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2004.031112"},{"key":"CIT0056","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.leu.2403307","volume":"18","author":"Deininger","year":"2004","journal-title":"Leukemia"},{"key":"CIT0057","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"CIT0058","first-page":"889","volume":"116","author":"Branford","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"CIT0059","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"key":"CIT0060","first-page":"3422","volume":"116","author":"Tsaur","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"CIT0061","first-page":"235","volume":"91","author":"Wang","year":"2006","journal-title":"Haematologica"},{"key":"CIT0062","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/asheducation-2005.1.183","volume":"2005","author":"Shah","year":"2005","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-103523"},{"key":"CIT0064","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1928"},{"key":"CIT0066","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"CIT0067","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.2174\/1389557043487321"},{"key":"CIT0069","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"CIT0070","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","volume":"27","author":"Hughes","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"CIT0071","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046839"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1516"},{"key":"CIT0074","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"CIT0075","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"key":"CIT0076","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"CIT0077","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","volume":"571","author":"von Bubnoff","year":"2002","journal-title":"Lancet"},{"key":"CIT0078","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1182\/blood.V99.5.1860","volume":"99","author":"Hofmann","year":"2002","journal-title":"Blood"},{"key":"CIT0079","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"CIT0080","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/leu.2009.299","volume":"24","author":"Hiwase","year":"2010","journal-title":"Leukemia"},{"key":"CIT0081","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","volume":"109","author":"Wang","year":"2007","journal-title":"Blood"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.20.1641"},{"key":"CIT0083","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"CIT0084","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"CIT0085","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"CIT0086","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/jco.2008.26.15_suppl.7009","volume":"26","author":"Mauro","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"CIT0087","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"key":"CIT0088","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"CIT0089","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2008-04-149948","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"CIT0090","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10822"},{"key":"CIT0091","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"CIT0092","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080838"},{"key":"CIT0093","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res."},{"key":"CIT0094","doi-asserted-by":"crossref","unstructured":"Bruemmendorf T, Cervantes F, Kim D, Chandy M, Fischer T, Hochhaus A. Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Presented at:44th ASCO Annual Meeting. Chicago, IL, USA, 30 May\u20133 June 2008.","DOI":"10.1200\/jco.2008.26.15_suppl.7001"},{"key":"CIT0095","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3324\/haematol.2009.012781","volume":"95","author":"Milojkovic","year":"2010","journal-title":"Haematologica"},{"key":"CIT0096","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1182\/blood-2010-07-293977","volume":"117","author":"Jabbour","year":"2010","journal-title":"Blood"},{"key":"CIT0097","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"CIT0098","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"CIT0099","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1182\/blood.V116.21.3410.3410","volume":"116","author":"Nicolini","year":"2010","journal-title":"Blood"},{"key":"CIT0100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood-2009-11-255026","volume":"116","author":"Cortes","year":"2010","journal-title":"Blood"},{"key":"CIT0101","doi-asserted-by":"crossref","unstructured":"Cortes-Franco J, Dombret H, Schafhausen Pet al.Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Presented at:51st Annual Meeting of American Society of Hematology. New Orleans, LA, USA, 5\u20138 December 2009.","DOI":"10.1182\/blood.V114.22.864.864"},{"key":"CIT0102","doi-asserted-by":"crossref","unstructured":"Cortes J, Roboz GJ, Kantarjian HMet al.A Phase I dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and Aurora in patients with relapsed\/refractory AML, ALL and MDS or resistant\/intolerant CML. Presented at:50th Annual Meeting of American Society of Hematology. San Francisco, CA, USA, 6\u20139 December 2008.","DOI":"10.1182\/blood.V112.11.2967.2967"},{"key":"CIT0103","unstructured":"Cortes JE, Wetzler M, Lipton Jet al.Subcutaneous omacetaxine (OM) treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients following multiple tyrosine kinase inhibitor (TKI) failure. Presented at:52nd Annual Meeting of American Society of Hematology. Orlando, FL, USA, 4\u20137 December 2010."},{"key":"CIT0104","doi-asserted-by":"crossref","unstructured":"Branford S, Kim D-W, Soverini Set al.Molecular response at 3 months on nilotinib therapy predicts response and long-term outcomes in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP). Presented at:51st Annual Meeting of American Society of Hematology. New Orleans, LA, USA, 5\u20138 December 2009.","DOI":"10.1182\/blood.V114.22.3292.3292"},{"key":"CIT0105","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood-2008-02-141580","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"CIT0106","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"Hughes","year":"2003","journal-title":"N. Engl. J. Med."}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/ehm.11.19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T04:36:41Z","timestamp":1637815001000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/ehm.11.19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":106,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,1,10]]},"published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1586\/ehm.11.19"],"URL":"https:\/\/doi.org\/10.1586\/ehm.11.19","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}